Gilead’s lenacapavir injection, part of its approved HIV treatment form Sunlenca, is up for approval as a preventive medication (PrEP) on June 19. The therapy claims to almost entirely prevent HIV transmission. However, the decision comes amid controversy surrounding recent federal politics and their impact on healthcare policies.
Source: https://endpoints.news/with-hiv-prevention-under-attack-how-might-gileads-new-prep-injection-fare